Ascendis director sells 236 shares at $264

Ascendis Pharma A/S director Lars Holtug sold a small block of shares and now holds 4,000 Ordinary Shares directly.

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) director Lars Holtug reported selling 236 Ordinary Shares on September 2, 2026 in an open-market or private transaction at $264.13 per share. After this sale, he directly holds 4,000 Ordinary Shares of Ascendis Pharma A/S.

No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Seller: 236 shares

Net Sell 1 txn

Insider HOLTUG LARS

Role Director

Sold 236 shs ($62K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	236	$264.1296	$62K

Holdings After Transaction: Ordinary Shares — 4,000 shares (Direct)

Key Figures

Shares sold: 236 shares Sale price per share: $264.13 per share Shares held after transaction: 4,000 shares +1 more

4 metrics

Shares sold 236 shares Ordinary Shares sold by director Lars Holtug on September 2, 2026

Sale price per share $264.13 per share Price for the 236 Ordinary Shares sold on September 2, 2026

Shares held after transaction 4,000 shares Direct holdings of Ordinary Shares by Lars Holtug following the sale

Net shares sold 236 shares Net share change across all reported transactions in this Form 4

Key Terms

Ordinary Shares, open-market or private transaction, Rule 10b5-1

3 terms

Ordinary Shares financial

"The reported transaction involves Ordinary Shares of Ascendis Pharma A/S"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market or private transaction financial

"Sale in open market or private transaction is listed as the code description"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did ASND director Lars Holtug report?

Director Lars Holtug reported a sale of 236 Ascendis Pharma A/S Ordinary Shares on September 2, 2026 in an open-market or private transaction.

At what price were the ASND shares sold by Lars Holtug?

The 236 Ascendis Pharma A/S Ordinary Shares were sold at a price of $264.13 per share, as reported in the Form 4 filing.

How many ASND shares does Lars Holtug hold after this transaction?

After the reported sale, Lars Holtug directly holds 4,000 Ordinary Shares of Ascendis Pharma A/S.

Was the ASND insider sale made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked, indicating that no Rule 10b5-1 trading plan is reported for this transaction.

What type of security did the ASND insider sell?

The reported transaction involves Ordinary Shares of Ascendis Pharma A/S, classified as a non-derivative security in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:15 PM Accepted by SEC EDGAR 09/03/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOLTUG LARS

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

DENMARK

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/02/2026		S		236	D	$264.1296	4,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael Wolff Jensen as attorney-in-fact for Lars Holtug	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)